The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 2, 2008, Pages 538-545

  Snider, Natasha T ^a   Sikora, Matthew J ^a   Sridar, Chitra ^a   Feuerstein, Thomas J ^b   Rae, James M ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CYTOCHROME P450 2D6;

ARTICLE; BRAIN MICROSOME; BRAIN MITOCHONDRION; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; NEUROCHEMISTRY; NEUROPSYCHIATRY; PHENOTYPE; PRIORITY JOURNAL;

8,11,14-EICOSATRIENOIC ACID; ARACHIDONIC ACID; ARACHIDONIC ACIDS; BRAIN; CYTOCHROME P-450 CYP2D6; EPOXY COMPOUNDS; HUMANS; HYDROXYLATION; MICROSOMES; MITOCHONDRIA; POLYUNSATURATED ALKAMIDES; TIME FACTORS;

EID: 54349118188     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.141796     Document Type: Article

References (32)

1. Bhagwat SV, Boyd MR, and Ravindranath V (2000) Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem Pharmacol 59:573-582.
2. Burstein SH, Rossetti RG, Yagen B, and Zurier RB (2000) Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61:29-41.
3. Capdevila JH and Falck JR (2001) The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285:571-576.
4. Craib SJ, Ellington HC, Pertwee RG, and Ross RA (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 134:30-37.
5. Cravatt BF and Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475.
6. Di Marzo V, Bifulco M, and De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784.
7. Dorado P, Peñas-Lledó EM, and Llerena A (2007) CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8:1597-1608.
8. Gelboin HV and Krausz K (2006) Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm. J Clin Pharmacol 46:353-372.
9. Gervasini G, Carrillo JA, and Benitez J (2004) Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 43:693-706.
10. Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, and Bornheim LM (1995) Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1259:173-179.
11. Hanna IH, Kim MS, and Guengerich FP (2001) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch Biochem Biophys 393:255-261.
12. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
13. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
14. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, and Marnett LJ (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277:44877-44885.
15. Kozak KR and Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66:211-220.
16. Krausz KW, Yang TJ, Gonzalez FJ, Shou M, and Gelboin HV (1997) Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem Pharmacol 54:15-17.
17. Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, and Bertilsson L (1993) Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23-28.
18. Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, and Agrò AF (1998) Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 273:32332-32339.
19. Miksys S, Rao Y, Hoffmann E, Mash DC, and Tyndale RF (2002) Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 82:1376-1387.
20. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
21. Petersdorf EW and Deeg HJ (1992) Diagnostic use of molecular probes before and after marrow transplantation. Clin Lab Med 12:113-128.
22. Roberts RL, Luty SE, Mulder RT, Joyce PR, and Kennedy MA (2004) Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 127B:90-93.
23. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622.
24. Siegle I, Fritz P, Eckhardt K, Zanger UM, and Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
25. Snider NT, Kornilov AM, Kent UM, and Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome P450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 321:590-597.
26. Steffens M, Schulze-Bonhage A, Surges R, and Feuerstein TJ (2005) Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci Lett 385:13-17.
27. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, and Baumann P (2000) Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855:235-243.
28. Woodland C, Huang TT, Gryz E, Bendayan R, and Fawcett JP (2008) Expression, activity and regulation of CYP3A in human and rodent brain. Drug Metab Rev 40:149-168.
29. Woodward DF, Liang Y, and Krauss AH (2008) Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 153:410-419.
30. Yu AM, Idle JR, Byrd LG, Krausz KW, Kü pfer A, and Gonzalez FJ (2003a) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173-181.
31. Yu AM, Idle JR, and Gonzalez FJ (2004) Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36:243-277.
32. Yu AM, Idle JR, Herraiz T, Küpfer A, and Gonzalez FJ (2003b) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319.